ICICI Securities's research report on Niva Bupa Health Insurance Company
Niva Bupa has been able to deliver standout growth in health insurance premiums (~40% CAGR between FY20–25 and 28% in Q1FY26 on a comparable basis (without 1/n). Alongside, the company’s improved scale and AUM should help it augment margins and earnings growth ahead (expect IFRS PAT CAGR of 55% over FY25–27E). The relatively accentuated growth and price hikes should also help Niva Bupa manage its loss ratios. Further, the company’s Q1FY26 expense ratio trend has already improved to align with EOM guidelines. Key risks include higher competitive intensity or claim denting profitability.
Outlook
Maintain BUY with revised TP of INR 92 (earlier INR 90)
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Niva Bupa Health Insurance Company_13082025_ICICI Securities
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
